TITLE

Intercept Expands Runway with $315M Asian Deal

PUB. DATE
April 2011
SOURCE
Bioworld Week;4/4/2011, Vol. 19 Issue 14, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the 315 million dollar agreement of Intercept Pharmaceuticals Inc. with Dainippon Sumitomo Pharma Co. Ltd. towards the development of its agonist obeticholic acid (OCA) drug INT-747 which treats chronic liver diseases.
ACCESSION #
60167020

 

Related Articles

  • Intercept Expands Runway with $315M Asian Agreement. Serebrov, Mari // BioWorld Today;3/31/2011, Vol. 22 Issue 62, p1 

    This article reports on a licensing agreement signed by Intercept Pharmaceuticals Inc. with Dainippon Sumitomo Pharma Co. Ltd. for the development and commercialization of Intercept's INT-747, an FXR agonist obeticholic acid (OCA) for the treatment of chronic liver diseases. Dainippon will...

  • Intercept Pharma NASH Drug Disappoints In Japan. AMY REEVES // Investors Business Daily;10/28/2015, p00 

    The article reports that Intercept Pharmaceuticals, a biopharmaceutical company, is trading down on October 28, 2015 following the first Japanese trial of its fatty-liver-disease drug. It states that the trial was conducted by company's partner Dainippon Sumitomo Pharma, and the result was a...

  • Intercept Pharma Dips As Analyst Doubts NASH Market. AMY REEVES // Investors Business Daily;8/13/2015, p00 

    The article reports that initial coverage of pharmaceutical firm Intercept Pharmaceuticals was rated by Morgan Stanley with an underperform, citing that the financial market is overestimating the opportunity in liver disease.

  • Dainippon Sumitomo Pharma to Buy Sepracor for $2.6 billion. Ramesh, Deepti // Chemical Week;9/14/2009, Vol. 171 Issue 23, p53 

    The article reports on the plan of Dainippon Sumitomo Pharma (DSP) of Osaka, Japan to purchase Sepracor, a pharmaceutical company located in Marlborough, Massachusetts. According to the author, the purchase of DSP will help enhance the company's marketing and sales capability in the U.S. and...

  • Pharma: Other News To Note.  // BioWorld Today;10/26/2012, Vol. 23 Issue 209, p9 

    This section offers news briefs on the pharmaceutical sector including the European Medicines Agency's acceptance of a review of the marketing application for lurasidone from Dainippon Sumitomo Pharma Co. Ltd. and Takeda Pharmaceutical Co. Ltd., approval received by Janssen-Cilag International...

  • Dainippon Sumitomo Licenses Japanese Rights to Two Redox-Directed Drugs from Edison Pharmaceuticals. Cartwright, Heather // PharmaDeals Review;2013, Vol. 2013 Issue 4, p43 

    The article focuses on the regional licensing partnership between Dainippon Sumitomo Pharma Co. Ltd. (DSP)and Edison Pharmaceuticals. It states that Japanese rights was licensed to DSP for the development and commercialisation of redox-directed drug candidates EPI-743 and EPI-589 of Edison...

  • Mintz Levin's Life Sciences Practice Represents Boston Biomedical Inc. in its Agreement with Dainippon Sumitomo Pharma Co., Ltd. to be Acquired for up to $2.63 Bln.  // Biomedical Market Newsletter;3/7/2012, Vol. 21, p1 

    The article reports on an agreement under which Dainippon Sumitomo Pharma Co. Ltd. (DSP) will acquire Boston Biomedical Inc (BBI) in 2.63 billion dollars. According to BBI, it has developed a world leading product pipeline targeting cancer stem cells which includes BBI608 and BBI503, as well as...

  • Dainippon and Takeda announce EMA acceptance of MAA for schizophrenia drug.  // PharmaWatch: CNS;Dec2012, Vol. 11 Issue 12, p17 

    The article reports on the European Medicines Agency (EMA) acceptance for review of the marketing authorization application (MAA) for schizophrenia drug received by Dainippon Sumitomo Pharma Co., Ltd. and Takeda Pharmaceutical Company Limited. The MAA for the antipsychotic medication lurasidone...

  • Dainippon Sumitomo Pharma Reports that Latuda(r) (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression.  // Biomedical Market Newsletter;5/7/2012, Vol. 21, p1 

    The article informs that Dainippon Sumitomo Pharma Co. Ltd. (DSP) has released results from its two Phase 3 clinical trials. The trials were designed to evaluate the efficacy and safety of LATUDA in patients withbipolar I depression. Both the studies found that patients recieving LATUDA...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics